ClinicalTrials.gg
Not yet recruitingNCT07499102Updated Oct 20, 2026

CK0801 for Treatment of Aplastic Anemia

A Phase 2 interventional study of CK0801 in Aplastic Anemia, sponsored by Cellenkos, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Cellenkos, Inc. · Phase 2, Interventional, and Treatment

Updated Oct 20, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This Phase 2, multicenter, open-label study is evaluating CK0801 for the treatment of aplastic anemia in adults with persistent transfusion dependence after at least one prior line of therapy or intolerance to standard-of-care treatment. CK0801 is an allogeneic cord blood-derived regulatory T-cell therapy administered intravenously. The study is designed to assess safety and clinical activity, including hematologic response, transfusion independence, duration of response, survival outcomes, and patient-reported outcomes. Exploratory assessments include immune reconstitution, biomarkers, pharmacokinetics, immunogenicity, and donor-specific antibodies. The primary endpoint is overall response at Day 180.

Read the detailed description

Aplastic anemia is a rare, life-threatening bone marrow failure disorder caused by immune-mediated destruction of hematopoietic stem and progenitor cells. Regulatory T cells (Tregs), which help maintain immune homeostasis, are decreased and functionally impaired in aplastic anemia. CK0801 is an allogeneic cord blood-derived Treg cell therapy being studied as a potential treatment to restore immune balance and improve hematopoiesis. Prior clinical experience described in the protocol showed a favorable safety profile and early signs of activity, including reduced transfusion requirements in patients with bone marrow failure.

This Phase 2, multicenter, open-label, single-agent study will evaluate the safety and efficacy of intravenous CK0801 in adults with aplastic anemia who remain transfusion dependent after at least one prior line of therapy or who are intolerant to standard-of-care treatment. A total of 12 participants are planned. CK0801 will be administered as a weight-based intravenous infusion, with protocol-defined premedication before treatment.

The primary endpoint is overall response at Day 180. Secondary endpoints include response at Days 28, 56, 100, and 365, time to best response, time to transfusion independence, duration of transfusion independence, immunosuppression-free survival, overall survival, progression-free survival, clonal evolution, patient-reported outcomes, and safety. Exploratory endpoints include donor-specific antibodies, immunosuppressive medication discontinuation, cytokine and biomarker changes, pharmacokinetics, immunogenicity, and immune reconstitution.

Enrollment will proceed using Simon's two-stage design. In Stage 1, 6 participants will be enrolled. If predefined activity criteria are met, the study will proceed to Stage 2 and enroll 6 additional participants, for a total of 12 participants. Participants will undergo protocol-defined clinical, laboratory, disease, safety, and correlative assessments. The overall study duration is expected to be approximately 24 months.

02

Conditions studied

  • Aplastic Anemia

Keywords

  • Aplastic Anemia
  • Bone Marrow Failure
  • CK0801
  • Regulatory T Cells
  • Treg Cell Therapy
  • Cord Blood-Derived Tregs
  • Allogeneic Cell Therapy
  • Transfusion Dependent
  • Immune Dysregulation
  • Open-Label Phase 2 Study
  • Cord Blood Unit
03

In context

Anemia, Aplastic

372 studies on the registry are indexed under Anemia, Aplastic; 99 are open to participants now.

This study's planned enrollment of 12 is below the median of 37 across 281 interventional studies indexed under Anemia, Aplastic.

Browse Anemia, Aplastic studies →

Lead sponsor

Cellenkos, Inc. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Diagnosis of aplastic anemia
  • Transfusion dependent after at least one , or intolerance to standard-of-care treatment
  • Female subjects of must have a negative urine or serum pregnancy test
  • Agrees to comply with all protocol-required procedures, including study-related assessments, visits, and long-term follow-up
  • Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Known seropositivity
  • Uncontrolled infection not responding to appropriate antimicrobial agents after 7 days of therapy; the Protocol PI is the final arbiter of eligibility
  • Uncontrolled intercurrent illness that, in the opinion of the investigator, would place the subject at greater risk of severe toxicity and/or impair the activity of CK0801
  • Pregnant or breastfeeding
  • Unable to provide consent or, in the opinion of the investigator, unlikely to fully comply with protocol requirements
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    CK0801

    All enrolled participants receive CK0801 administered intravenously according to the protocol. CK0801 is given as a weight-based dose of 1 x 10\^7 Tregs/kg using actual body weight, capped at 100 kg, on Study Day +1.

    Drug: CK0801

Interventions

  • DrugCK0801

    CK0801 is an investigational allogeneic, cord blood-derived regulatory T-cell product administered by intravenous infusion. The planned dose is 1 x 10\^7 CK0801 Tregs/kg using actual body weight, capped at 100 kg.

06

What researchers measure

Primary outcomes

  1. Primary Outcome-Overall Response Rate (ORR) at Day 180

    Overall response rate (ORR), defined as the proportion of subjects achieving either a complete response (CR) or partial response (PR) following treatment with CK0801.

    Time frame: Day +180

  2. Overall Response Rate at Additional Timepoints

    Proportion of subjects achieving CR or PR at earlier and later timepoints following treatment

    Time frame: Days 28, 56, 100, and 365

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Aug 2028, 20 months later.

Of 60 phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 104. This study's planned 20 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Mar 30, 2026
StartEst.
Dec 3, 2026was Aug 2026
Primary completionEst.
Aug 3, 2028
CompletionEst.
Aug 3, 2029
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 3, 2026→Dec 3, 2026
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Start date Aug 3, 2026→Dec 3, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07499102
Lead sponsor
Cellenkos, Inc.
Responsible party
Sponsor
First posted
Mar 30, 2026
Start date
Dec 3, 2026 (estimated)
Primary completion
Aug 3, 2028 (estimated)
Completion
Aug 3, 2029 (estimated)
Last update
Oct 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CK-0802

Start the discussion